Rights and permissions
About this article
Cite this article
Sorafenib a worthy opponent for advanced renal cancer. Inpharma Wkly. 1599, 6 (2007). https://doi.org/10.2165/00128413-200715990-00012
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200715990-00012